KRAS is the predominant mutated isoform in CRC (86%), whereas NRAS mutations are infrequent (14%) and HRAS mutations have not been detected.2 Genomic RAS mutations (in both KRAS and NRAS) are thought to be present in up to 47% of colorectal cancers.3,4. This evidence concerns the gene KRAS and colorectal carcinoma.